Pfizer to conduct trials of antiviral Covid-19 pill in Russia
Coronavirus chronicle
16 November, 2021, 04:00 pm
Last modified: 16 November, 2021, 04:04 pm
Pfizer said earlier this month the experimental antiviral pill cut by 89% the chance of hospitalisation or death for adults at risk of severe disease
FILE PHOTO: A refrigerated truck leaves the Pfizer plant in Puurs, Belgium December 3, 2020. REUTERS/Yves Herman/File Photo
Russia has granted approval for Pfizer Inc to conduct clinical trials in Russia of its experimental antiviral pill to treat Covid-19, a state registry of medicines showed on Tuesday.
The trials conducted on 90 people located in home-like conditions with someone who has symptomatic Covid-19 began on Nov. 12 and will continue until March 2023, the registry's website said.
Pfizer said earlier this month the experimental antiviral pill cut by 89% the chance of hospitalisation or death for adults at risk of severe disease. It hopes to make the pill available globally as quickly as possible.
The pill has the brand name Paxlovid.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.